Tirzepatide: A Breakthrough in fit-Tul Piż Ġestjoni u Obeżità Trattament

Tirzepatide: A Breakthrough in Fit-Tul Piż Ġestjoni u Obeżità Trattament  

Tirzepatide is a GLP-1 receptor dual agonist li reċentement been approvat in China for long-term weight management. Developed by Eli Lilly and Company, its biggest selling point lies in in its significant weight loss effect and comparative trial performance with other similar products on the market. Skont lil ir-riżultati ta' is-SURMOUNT-1 u SURMOUNT-2 Phase III clinical trials, after 72 weeks of use, the weight loss effects of the 15mg and 10mg dosage groups reached 20.9% and 19.5% rispettivament, making it the first drug in Phase III clinical trials to have an average weight loss of more than 20%.

Il piż telf indikazzjoni ta' Tirzepatide is suitable for adults with a body mass index (BMI) li jissodisfa dan li ġej rekwiżiti fuq il bażi ta a b'kaloriji baxxi dieta u żieda eżerċizzju: BMI Greater than or equal 28 kg/m² (obeżità), or BMI Greater than or equal 24 kg/m² (piż żejjed) ma at least wieħed weight-related comorbidity, such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, kardjovaskulari mard, eċċ.

Il- SURMOUNT-CN Phase III clinical study conducted in the Chinese population showed that at the 52nd week, the weight loss of obese and overweight adult patients treated with Tirzepatide reached up to 19.9%. This effect shows a greater potential for weight loss comcomped with other similar products on the market.

Il- sigurtà profil ta' Tirzepatide is similar to other GLP-1 receptor agonists, with the most common adverse reactions being mild to moderat gastrointestinal reactions, li prinċipalment occur matul id-doża eskalazzjoni perjodu u tnaqqis ma kontinu amministrazzjoni, u l-aktar pazjenti jistgħu jittolleraw u jaderixx mat it-trattament .

Ma l-approvazzjoni ta Tirzepatide in China, it will compete with other similar products in China's GLP-1 market. As a GIP/GLP{-1 dual-target drug, it shows a a stronger potential in weight loss effects. It is expected li with the launch of these two drugs in the Chinese market, they will bring new options and hope to the field of obesity treatment.

GenoHope Biotech Ltd.
A leading manufacturer of GLP-1 API
Approal by FDA
Merħba kwalunkwe Inkjesta
WhatsApp/Tel:+8613833133635
Email:info@genohopebio.com